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INTRODUCTION 
Infection with HIV results in profound immunologic changes in the infected host. The host 
immune system becomes dysregulated and profoundly suppressed culminating in a condition 
known as AIDS. Although this concept is well accepted, the actual immunopathology of the 
disease is far from established. 
Accumulated evidence have shown that the activation or misactivation of the immune 
system itself may contribute to disease progression (Pantaleo and Fauci, 1994). Thus, higher 
levels of activated CDS+ T cells have been shown to correlate with poorer clinical status and 
lower CD4+ T cell count (Giorgi eta/. 1993). Although measurement of the CD4+ T cell level 
is the current "gold standard" used as a prognostic marker of HIV-disease, it is highly variable 
among different individuals or even within the same individual. In fact, we have recently 
demonstrated that the percentage of C04+ T cell, a marker suggested to be more stable and 
less variable than the CD4+ T cell absolute count (Taylor et a/. 1989) may not necessarily be 
suitable to be used as a HIV-disease marker for our local stituation (Norazmi and Suam, 
1994). These data point to the need for separate studies in populations and risk groups other 
than white homosexual men to identify and clarify prognostic indicators for the development 
of AIDS. 
Thus, the possible use of other markers such as activated T cell subsets are being sought, 
aimed to at least increase the predictive value of CD4+ count, if not to replace it. Since IVDU 
is the most important risk group for the transmission of this disease in Malaysia, the 
detennination of changes in the cellular activation profile in this group may provide valuble 
infonnation on the immunopathology of the disease. 
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OBJECTIVE 
The aim of this study was to determine any changes in the subsets of CDS+ T cell expressing 
one or both of the two selected activation markers i.e. CD38 & HLA-DR using 3-colour 
immuno-flowcytometry. 
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MATERIALS & METHODS 
Subjects: 
Intravenous drug users (IVDU) (all women, aged 20-45 years) at Pusat SERENTI, 
Pengkalan Chepa were grouped into HIV-seropositive and HIV seronegative (by both ELISA 
and We stem blotting). 
Cellular Activation Markers: 
The activation markers, HLA-DR and CD3S on CDS+ T cells which have been 
proposed to have a predictive value for assessing disease progression (Kestens et at. 1992; 
Levacher et a/. 1992) were used. Total lymphocyte population and percentage of CD4+ T 
cells were also determined for comparison. Panel of mouse monoclonal antibody used is 
shown in Table 1. 
Table 1: Panel of mouse monoclonal antibody (Beckton Dickinson). 
Panel FL1 (FITC) Specificity FL2(PE) Specificity FL3 (PerCP) Specificity 
1 lgG1 lsotype lgG1 lsotype lgG1 lsotype 
control control control 
2 CD4 Th subset CDS Ts CD3 Total T 
3 CD3 Total T CD16/56 NK cells C019 B cells 
4 HL.A-DR MHC II C038 Activated CDS Ts 
cells 
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Sample Preparation: 
lmmunophenotyping of the cellular marker were carried out using three-colour flow cytometry 
(FITC, Phycoerythrin, & Peridinium chlorophyll protein). Peripheral blood from the subjects 
were obtained via venepuncture and collected in sterile tubes containing ethylene diamine 
tetracetate (EDTA). The specimens collected were processed within 2 hours of drawing. 
White cell and differential counts were performed on at leasr 5000 and 3,000 cells 
respectively using a Haematology Counter. High resolution flow cytometric analysis was 
perfonned on peripheral blood samples prepared using standardised lysed whole blood 
methods (Loken eta/. 1990). Briefly, 100 ul of whole blood samples were placed into a set of 
polystyrene tubes containing 1 0 ul of matching combination of murine monoclonal antibodies 
directly conjugated with FITC, PE and PerCP (Beckton Dickinson). The samples were then 
incubated in the dark for 15 min at room temperature after which the RBC were lysed in 2 ml 
of FACS Lysing solution (Beckton Dickinson). The tubes were then centrifuges and the cells 
were washed once in PBS, pH 7.2, and fixed in 1% formaldehyde and 10,000 cells were 
analysed in the FACScan using the L YSYS II Software (Beckton Dickinson). 
3-co/our immuno-flowcytometry 
In this study, 3-colour immuno-flowcytometry analysis of HLA-DR, CDS and CD38 cells was 
performed. Samples were light scatter gated on lymphocytes. In analysing the fluoresent 
plots for activation cell markers, a 'logical markers' were set when necessary to provide a 
more realistic representation of the stained population. Thus, marker settings were adjusted 
to best differentiate between fairly discrete cell populations. 
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The result of immuno-flowcytometry analyses is shown in Table 2. Our result show that the 
percentage level of CD4+ T cells decreased dramatically in HIV+ IVDU compare to HIV-
IVDU. In contrast, the percentage level of CDS+ T cells increased in HIV+ IVDU compare to 
HIV- IVDU. These findings are consistent with the previous observation as reported by many 
researchers (Fahey eta/. 19S4; Brinchmann eta/. 1989; Kaslow eta/. 1990). 
Table 2: Expression of the activation markers on CDS+ T cells (mean % + S.D) 
SUBSET HIV -ve HIV +ve Unpaired t test (p<) 
(n=10) (n=13) 
CD4 36.2 + 3.4 14.2 + 9.3 0.0001 
cos 23.3. + 6.1 47.3 + 11.9 0.001 
C08+/Hl.A-DR+/CD3S+ 12.0 + 5.5 41.7 + 16.6 0.002 
CD8+/Hl.A-DR-/CD38+ 27.9 + 2.0 43.5 + 9.1 0.03 
CD8+/HLA-DR-/CD38- 54.0 + 28.6 8.7+ 8.3 0.004 
CD8+/HLA-DR+/CD38- 6.1 + 8.2 3.3+ 3.8 n.s 
With regard to activation status, percentage levels of two subsets, CD8+/HLA-DR+/C038+ 
and CD8+/HLA-DR-/CD38+ were found to be higher in HIV+ve IVDU compared to HIV-ve 
IVDU. In contrast, percentage level of CD8+/H~-OR-/CD38- subset is lower in HIV+ve IVDU 
compared to HIV-ve IVDU, whereas percentage level of CD8+/HLA-DR+/CD38- is not 
significantly different between the two groups. 
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DISCUSSION 
The complexity of HIV disease process reflected in the heterogeneity of the clin~cal course of 
individual infected patients, makes monitoring solely by clinical criteria unsatisfactory. There 
is thus a need for biologic markers to aid in the monitoring of HIV disease progression and 
the response to therapy. Profound changes of immune cellular activation occur shortly after 
infection with HIV and persist throughout the disease course. 
CD4 lymphocyte subsets, expressed as an absoulute count or as a percentage of total 
lymphocyte is one of the most important correlates with the disease stage. In addition, CD4 
count is also useful in defining patients at risk of developing opportunistic infections and in 
guiding preventive treatments. However, there are some problems in relying solely on this 
parameter at the individual level. CD4 count has been shown to be highly variable among 
different individuals or even within the same individual (Gorter et at. 1992, Norazmi & Suam, 
1995). There is considerable over1ap in CD4 counts among the clinically defined stages of 
HIV infection. 
Thus, the possible use of other surrogate markers are actively being sought and enumeration 
of activated T lymphocyte subsets is therefore one obvious choice, since this marker has 
been shown to correlate with poorer clinical status and lower CD4 count (Giorgi et at. 1993). 
The display of activation markers such as CD38 and HLA-DR increases significantly on cos 
T cells in HIV infection (Levacher eta/. 1992) 
In this study, consistent with many previous studies (Fahey eta/., 1984; Brinchmann et al. 
1989), we demonstrated that CD4 levels were decreased and CD8 levels were increased in 
HIV seropositive IVDU compared to HIV-seronegative IVDU. Elimination of CD4 cells may 
be partly due to apotosis initialy triggered by HIV infection (Gougeon and Montagnier, 1993). 
our study also showed that certain activation markers on CD8 subsets were increased in 
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HIV-infected IVDU. Two subsets of CDS T cells (CD8+/HLA-DR+/C038+; CD8+/HLA-DR-
/CD38+) from HIV-infected IVDU were observe to increased. Gradual progression of (the two 
activation markers) HLA-DR+CD38-, HLA-DR+CD38+ towards HLA-DR-CD38+ following 
progression in HIV can be seen, however direct correlation with decline in CD4 absolute 
count were not found in this study. 
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CONCLUSIONS 
Our study and many others suggested that T cell activation is related to disease progression. 
The changes in these cellular activation profile may provide additional surrogate markers for 
HIV-disease progression, in addition to the CD4 count. Further studies include assessment of 
the expression of those activation markers on the yo T cell population since this subset has 
also been shown to be increased in HIV-infection (Norazmi eta/. 1995; Mohd-Nor eta/. 1995; 
Margolick eta/. 1991). 
10 
11 
ACKNOWLEDGEMENT 
We would like to express our appreciation to the people and staff of Pusat SERENTI, 
Pengkalan Chepa for their supports that they have offered throughout this project. 
We also wish to thank En. Jamaruddin Mat Asan and Pn Azma Hayati Abdullah for helping 
us in the practical aspect of flow cytometry. 
The authors acknowledge the research grant provided by Universiti Sains Malaysia, Penang 
that has resulted in this report. 
11 
12 
REFERENCES 
Brinchmann JE, Vardal F, Thorsby E (1989). J. AIDS. 2:398-403. 
Fahey JL, Prince H, Weaver M, Groopman J, Visscher B, Schwart K, Detel R (1984). Am. J. 
Med. 76: 95-100 
Giorgi JV, Liu Z, Hultin LE, Cumberland WG, Hennessey K, & Detels R (1993): J. Acquir. 
Immune Defic. Syndr. 6:904-912. 
Gougeon ML & Montagnier L. (1993). Science. 260: 1269-1270. 
Kaslow RA, Duquesnoy R, van raden Metal. (1990). Lancet. 335: 927-930. 
Kestens L, vanham G, Gigase P, Young G, Hannet I, Vanlangendonck F, Hulstaert F & Bach 
BA. (1992). AIDS. 6:793-797. 
Levacher M, Hulstaert S, Tallet S, Ullery S, Pocidalo JJ & Bach BA. (1992). Clin. Exp. 
lmmunol. 90: 376-382. 
Loken MR, Brosnan JM, Bach BA, & Ault KA (1990). Cytometry. 11:453-459. 
Margolick JB, scott ER, Odaka N & Saah AJ. (1991). Clin. lmmunol. lmmunopathol. 58: 126_ 
138. 
N N A
rifin H & Jamaruddin MA (1995). lmmunol. & Cell Bioi. 73: 245-248 
Mohd. or , · 
. d suam. (1994). lmmunol. Letters. 43:177-182. 
Norazm• an 
12 
13 
Norazmi, Jamaruddin MA & Arifin H (1995). Asia Pac. J. Mol. Bioi. & Biotechnol. 3: 119-129. 
Pantaleo and Fauci (1994): Curr. Opi. lmmunol. 6:600-604. 
Taylor et al. (1989). J Acquir. Immune. Defic. Syndr. 2:114-124. 
13 
